Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders

Show simple item record

dc.contributor.author Fisher, Miranda L.
dc.contributor.author Loukola, Anu
dc.contributor.author Kaprio, Jaakko
dc.contributor.author Turner, Jill R.
dc.contributor.editor DeBiasi, Mariella
dc.date.accessioned 2017-09-14T09:59:26Z
dc.date.available 2021-12-17T18:48:08Z
dc.date.issued 2015
dc.identifier.citation Fisher , M L , Loukola , A , Kaprio , J & Turner , J R 2015 , Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders . in M DeBiasi (ed.) , NICOTINE USE IN MENTAL ILLNESS AND NEUROLOGICAL DISORDERS . 1. p. edn , International Review of Neurobiology , vol. 124 , ACADEMIC PRESS INC ELSEVIER SCIENCE , pp. 113-131 . https://doi.org/10.1016/bs.irn.2015.07.006
dc.identifier.other PURE: 64757562
dc.identifier.other PURE UUID: 96ffada5-6944-485a-a06e-c1879c49ff19
dc.identifier.other WOS: 000376192100005
dc.identifier.other Scopus: 84941703039
dc.identifier.other ORCID: /0000-0003-0542-5967/work/28947743
dc.identifier.uri http://hdl.handle.net/10138/224172
dc.description.abstract Smoking is currently the leading cause of preventable death in the United States and is responsible for over four million deaths annually worldwide. Therefore, there is a vast clinical unmet need with regards to therapeutics targeting smoking cessation. This is even more apparent when examining smokers co-morbid with psychiatric illness, as rates of smoking in this population are similar to 4 x higher than in the general population. Examining common genetic and molecular signaling pathways impinging upon both smoking behavior and psychiatric illness will lead to a better understanding of co-morbid disorders and potential development of novel therapeutics. Studies have implicated the Neuregulin Signaling Pathway in the pathophysiology of a number of psychiatric illnesses. Additionally, recent studies have also shown an association between the Neuregulin Signaling Pathway and smoking behaviors. This review outlines basic mechanisms of the Neuregulin Signaling Pathway and how it may be exploited for precision medicine approaches in treating nicotine dependence and mental illness. en
dc.format.extent 19
dc.language.iso eng
dc.publisher ACADEMIC PRESS INC ELSEVIER SCIENCE
dc.relation.ispartof NICOTINE USE IN MENTAL ILLNESS AND NEUROLOGICAL DISORDERS
dc.relation.ispartofseries International Review of Neurobiology
dc.relation.isversionof 978-0-12-801583-4
dc.relation.isversionof 9780128016268
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject SUSTAINED-RELEASE BUPROPION
dc.subject RANDOMIZED CONTROLLED-TRIAL
dc.subject RECEPTOR TYROSINE KINASE
dc.subject SMOKING-CESSATION
dc.subject CIGARETTE-SMOKING
dc.subject SUSCEPTIBILITY LOCI
dc.subject MAJOR DEPRESSION
dc.subject BIPOLAR DISORDER
dc.subject PARTIAL AGONIST
dc.subject NERVOUS-SYSTEM
dc.subject 3112 Neurosciences
dc.subject 3124 Neurology and psychiatry
dc.subject 3142 Public health care science, environmental and occupational health
dc.title Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders en
dc.type Chapter
dc.contributor.organization Clinicum
dc.contributor.organization Department of Public Health
dc.contributor.organization Jaakko Kaprio / Principal Investigator
dc.contributor.organization Institute for Molecular Medicine Finland
dc.contributor.organization Genetic Epidemiology
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1016/bs.irn.2015.07.006
dc.relation.issn 0074-7742
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0074774215000525_main.pdf 371.6Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record